X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs STRIDES SHASUN LTD - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. STRIDES SHASUN LTD WOCKHARDT LTD./
STRIDES SHASUN LTD
 
P/E (TTM) x -23.6 38.1 - View Chart
P/BV x 2.4 0.9 252.2% View Chart
Dividend Yield % 0.0 1.0 0.2%  

Financials

 WOCKHARDT LTD.   STRIDES SHASUN LTD
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
STRIDES SHASUN LTD
Mar-17
WOCKHARDT LTD./
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,0121,275 79.4%   
Low Rs532918 57.9%   
Sales per share (Unadj.) Rs355.9389.6 91.4%  
Earnings per share (Unadj.) Rs-60.328.0 -215.5%  
Cash flow per share (Unadj.) Rs-46.848.9 -95.6%  
Dividends per share (Unadj.) Rs0.014.50 0.2%  
Dividend yield (eoy) %00.4 0.3%  
Book value per share (Unadj.) Rs257.8303.1 85.1%  
Shares outstanding (eoy) m110.6389.42 123.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.22.8 77.1%   
Avg P/E ratio x-12.839.2 -32.7%  
P/CF ratio (eoy) x-16.522.4 -73.6%  
Price / Book Value ratio x3.03.6 82.8%  
Dividend payout %016.1 -0.1%   
Avg Mkt Cap Rs m85,37998,036 87.1%   
No. of employees `0006.35.8 107.8%   
Total wages/salary Rs m9,3715,881 159.3%   
Avg. sales/employee Rs Th6,295.06,005.9 104.8%   
Avg. wages/employee Rs Th1,498.31,014.0 147.8%   
Avg. net profit/employee Rs Th-1,066.3431.2 -247.3%   
INCOME DATA
Net Sales Rs m39,36934,834 113.0%  
Other income Rs m1,2021,686 71.3%   
Total revenues Rs m40,57136,520 111.1%   
Gross profit Rs m186,428 0.3%  
Depreciation Rs m1,4951,872 79.9%   
Interest Rs m2,5552,269 112.6%   
Profit before tax Rs m-2,8303,973 -71.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m-3,582-1,006 356.2%   
Tax Rs m257470 54.7%   
Profit after tax Rs m-6,6692,501 -266.6%  
Gross profit margin %018.5 0.3%  
Effective tax rate %-9.111.8 -76.8%   
Net profit margin %-16.97.2 -235.9%  
BALANCE SHEET DATA
Current assets Rs m33,79638,165 88.6%   
Current liabilities Rs m26,91730,402 88.5%   
Net working cap to sales %17.522.3 78.4%  
Current ratio x1.31.3 100.0%  
Inventory Days Days7977 102.6%  
Debtors Days Days89104 85.4%  
Net fixed assets Rs m39,66437,639 105.4%   
Share capital Rs m553894 61.9%   
"Free" reserves Rs m27,96826,210 106.7%   
Net worth Rs m28,52227,105 105.2%   
Long term debt Rs m21,73116,377 132.7%   
Total assets Rs m81,62081,168 100.6%  
Interest coverage x-0.12.8 -3.9%   
Debt to equity ratio x0.80.6 126.1%  
Sales to assets ratio x0.50.4 112.4%   
Return on assets %-5.05.9 -85.8%  
Return on equity %-23.49.2 -253.4%  
Return on capital %-7.712.1 -63.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80713,465 72.8%   
Fx outflow Rs m1,7894,076 43.9%   
Net fx Rs m8,0199,389 85.4%   
CASH FLOW
From Operations Rs m6842,881 23.8%  
From Investments Rs m6,302-7,051 -89.4%  
From Financial Activity Rs m-7,6953,382 -227.5%  
Net Cashflow Rs m-664-788 84.3%  

Share Holding

Indian Promoters % 74.5 27.7 269.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 37.8 6.1%  
FIIs % 7.7 8.6 89.5%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 25.9 59.5%  
Shareholders   67,757 56,241 120.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  PLETHICO PHARMA  TTK HEALTHCARE  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Losses; Rupee Devalues to Record Low(12:30 pm)

Stock markets in India trim losses to turn flat even as rupee fell 43 paise to hit record low of 70.29 against the US dollar.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Aug 16, 2018 03:05 PM

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - GSK PHARMA COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS